Compare · DCOY vs MRK
DCOY vs MRK
Side-by-side comparison of Decoy Therapeutics Inc. (DCOY) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DCOY and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $363.98B, about 201282.8x DCOY ($1.8M).
- Over the past year, DCOY is down 95.1% and MRK is up 75.5% - MRK leads by 170.6 points.
- DCOY has been more active in the news (10 items in the past 4 weeks vs 6 for MRK).
- MRK has more recent analyst coverage (25 ratings vs 1 for DCOY).
- Company
- Decoy Therapeutics Inc.
- Merck & Company Inc.
- Price
- $2.80+5.66%
- $147.52-0.65%
- Market cap
- $1.8M
- $363.98B
- 1M return
- -32.69%
- +12.70%
- 1Y return
- -95.06%
- +75.55%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 10
- 6
- Recent ratings
- 1
- 25
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest DCOY
- Director Lieber Jonathan I was granted 2,000 shares, increasing direct ownership by 100,000% to 2,002 units (SEC Form 4)
- Chief Business Officer Marschel Peter Klaus was granted 3,900 shares (SEC Form 4)
- Chief Executive Officer Pierce Frederick Ii was granted 33,455 shares, increasing direct ownership by 2,409% to 34,844 units (SEC Form 4)
- Chief Financial Officer Rosenblum Mark J was granted 9,682 shares, increasing direct ownership by 576% to 11,363 units (SEC Form 4)
- Chief Scientific Officer Hibner Barbara Louise was granted 4,216 shares (SEC Form 4)
- Director Hanish Arnold C was granted 3,000 shares, increasing direct ownership by 718% to 3,418 units (SEC Form 4)
- Director Lammers Paul was granted 2,000 shares, increasing direct ownership by 200,000% to 2,001 units (SEC Form 4)
- Director Burleson Tess was granted 2,000 shares, increasing direct ownership by 100,000% to 2,002 units (SEC Form 4)
- Director Mcvicar William K. was granted 3,000 shares, increasing direct ownership by 150,000% to 3,002 units (SEC Form 4)
- Director Gauthier Patricia G. was granted 2,000 shares (SEC Form 4)
Latest MRK
- Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
- Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
- New insider Gupta Gaurav K claimed ownership of 750 shares (SEC Form 3)
- Merck downgraded by RBC Capital Mkts with a new price target
- Merck upgraded by Morgan Stanley with a new price target
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
- EVP, Access, Policy & Comms Guindo Chirfi sold $1,350,000 worth of shares (10,000 units at $135.00), decreasing direct ownership by 21% to 36,613 units (SEC Form 4)
- EVP, General Counsel Zachary Jennifer exercised 54,927 shares at a strike of $109.78 and sold $10,718,495 worth of shares (80,315 units at $133.46), decreasing direct ownership by 36% to 45,509 units (SEC Form 4)
- EVP&Pres, Merck Animal Heallth Deluca Richard R. sold $5,942,369 worth of shares (45,320 units at $131.12), decreasing direct ownership by 29% to 110,167 units (SEC Form 4)
- Merck upgraded by Daiwa Securities with a new price target